Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia

Yi Zhu, Xiwen Tong, Bin Xu, Shiyuan Zhang, Andie Fu, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 6989.

https://doi.org/10.1182/blood-2025-6989

Published: 2025

Journal Articles

ZFP36L2 as a promising therapeutic target in acute graft-versus-host disease: Evidence from murine models and clinical validation

Li Li, Andie Fu, Xiwen Tong, Bin Xu, Xia Mao, Ying Wang, Shiyuan Zhang, Yi Zhu, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 5863.

https://doi.org/10.1182/blood-2025-5863

Published: 2025

Journal Articles

SH2B3 expression predicts selinexor sensitivity in acute myeloid leukemia

Shiyuan Zhang, Longlong Liu, Bin Xu, Xiwen Tong, Andie Fu, Shuai Su, Yi Zhu, Zhuoxin Wen, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 7016.

https://doi.org/10.1182/blood-2025-7016

Published: 2025

Journal Articles

Rapid bone marrow blast reduction-guided selinexor-based regimen therapy in relapsed/refractory and newly diagnosed acute myeloid leukemia

Yi Zhu, Shuai Su, Bin Xu, Shiyuan Zhang, Zhuoxin Wen, Xiwen Tong, Andie Fu, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 5223.

https://doi.org/10.1182/blood-2025-5223

Published: 2025

Journal Articles

Selinexor-based non-intensive chemotherapy regimens adjusted according to early responses achieve high early remission in newly diagnosed AML or MDS

Shiyuan Zhang, Shuai Su, Bin Xu, Xiwen Tong, Yi Zhu, Andie Fu, Zhuoxin Wen, Zhiqiong Wang, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 1673.

https://doi.org/10.1182/blood-2025-1673

Published: 2025

Journal Articles

Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Xiwen Tong, Bin Xu, Shiyuan Zhang, Xiaojian Zhu, Mengyuan Li, Su Shuai, Yi Zhu, Zhenqian Huang, Yaya Wang, Yi Xiao, Liang Huang, Dengju Li, Wei Huang, Jia Wei, Mei Huang, Zhiping Huang, Yuanyan Tang, Hongbo Ren, Donghua Zhang

Blood (2024) 144 (Supplement 1): 4276.

https://doi.org/10.1182/blood-2024-205769

Published: 2024

Journal Articles

Selinexor in Combination with Standard or Reduced-Dose Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Multiple Myeloma

Su Shuai, Bin Xu, Chunrui Li, Di Wang, Xiwen Tong, Yi Zhu, Xia Mao, Min Xiao, Donghua Zhang

Blood (2024) 144 (Supplement 1): 7062.

https://doi.org/10.1182/blood-2024-204278

Published: 2024

Journal Articles

Impact of Selinexor on AML Cell Lines and Healthy Donor T Cell Function: Enhanced Treg Cell Proportion

Xiwen Tong, Xiaojian Zhu, Su Shuai, Yi Zhu, Bin Xu, Yizhou Peng, Shiyuan Zhang, Jin Jie, Xia Mao, Jia Wei, Donghua Zhang

Blood (2024) 144 (Supplement 1): 5817.

https://doi.org/10.1182/blood-2024-205174

Published: 2024

Journal Articles

The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients

Shiyuan Zhang, Mengyuan Li, Xiaojian Zhu, Hao Zhou, Bin Xu, Xiwen Tong, Su Shuai, Yi Zhu, Yi Xiao, Liang Huang, Dengju Li, Wei Huang, Jia Wei, Mei Huang, Donghua Zhang

Blood (2024) 144 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2024-205864

Published: 2024

Journal Articles

Prognostic and Therapeutic Implications of Early Assessment in AML and MDS Patients Treated with Selinexor-Containing Chemotherapy-Free Regimen

Su Shuai, Bin Xu, Xiwen Tong, Yi Zhu, Shiyuan Zhang, Xia Mao, Zhiqiong Wang, Min Xiao, Donghua Zhang, Jia Wei

Blood (2024) 144 (Supplement 1): 6004.

https://doi.org/10.1182/blood-2024-205664

Published: 2024

Journal Articles

Selinexor-Based Chemotherapy-Free or Low-Dose Chemotherapy Regimens in Acute Myeloid Leukemia, Myelodysplastic Syndromes: Efficacy and Safety

Xiwen Tong, Bin Xu, Su Shuai, Yi Zhu, Jin Jie, Yizhou Peng, Li Li, Mengyuan Li, Xia Mao, Wei Huang, Donghua Zhang, Jia Wei

Blood (2024) 144 (Supplement 1): 6003.

https://doi.org/10.1182/blood-2024-205493

Published: 2024

Journal Articles

Real-World Experience with Selinexor -Containing Regimens in Post-Transplant AML/MDS Patients Who MRD Still Positive after First-Line Preemptive Treatment

Xiwen Tong, Shuai Su, Bin Xu, Xiaojian Zhu, Yizhou Peng, Jin Jie, Xia Mao, Min Xiao, Jay Mei, Donghua Zhang

Blood (2023) 142 (Supplement 1): 5837.

https://doi.org/10.1182/blood-2023-186006

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia

ZFP36L2 as a promising therapeutic target in acute graft-versus-host disease: Evidence from murine models and clinical validation

SH2B3 expression predicts selinexor sensitivity in acute myeloid leukemia

Rapid bone marrow blast reduction-guided selinexor-based regimen therapy in relapsed/refractory and newly diagnosed acute myeloid leukemia

Selinexor-based non-intensive chemotherapy regimens adjusted according to early responses achieve high early remission in newly diagnosed AML or MDS

Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Selinexor in Combination with Standard or Reduced-Dose Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Multiple Myeloma

Impact of Selinexor on AML Cell Lines and Healthy Donor T Cell Function: Enhanced Treg Cell Proportion

The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients

Prognostic and Therapeutic Implications of Early Assessment in AML and MDS Patients Treated with Selinexor-Containing Chemotherapy-Free Regimen

Selinexor-Based Chemotherapy-Free or Low-Dose Chemotherapy Regimens in Acute Myeloid Leukemia, Myelodysplastic Syndromes: Efficacy and Safety

Real-World Experience with Selinexor -Containing Regimens in Post-Transplant AML/MDS Patients Who MRD Still Positive after First-Line Preemptive Treatment

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only